文献速递临床试验与 GCP流行病学与生物统计

非ICU病房血流感染7天与14天抗生素疗程的初步随机对照试验

A pilot randomized controlled trial of 7 versus 14 days of antibiotic treatment for bloodstream infection on non-intensive care versus intensive care wards.
PubMed 文献 · Trials · 2020-01-15

BALANCE-Ward初步随机对照试验在6个参与BALANCE主试验的中心招募非ICU病房血流感染患者,随机接受7天或14天抗生素治疗,评估招募可行性和方案依从性。共招募134例患者,招募率超过BALANCE-ICU初步试验,方案依从性为93%也高于ICU试验的77%,90天死亡率为12.8%与ICU试验的14.8%相当。结论认为在非ICU患者中开展7天与14天抗生素疗程的试验是可行的。

要点

  • 非ICU病房血流感染患者随机接受7天或14天抗生素治疗是可行的。
  • 招募率(平均2.9例/中心-月)和方案依从性(93%)均超过ICU初步试验。
  • 非ICU患者90天死亡率为12.8%,与ICU试验的14.8%相当。

核心结论

  • 在非ICU病房血流感染患者中开展7天与14天抗生素疗程的随机试验是可行的。
  • 将BALANCE主试验扩展至全院范围可能提高试验结果的时效性和普遍性。

研究设计与样本

  • 开放标签初步随机对照试验,在6个参与BALANCE主试验的中心进行。
  • 纳入非ICU病房血培养非金黄色葡萄球菌阳性的血流感染患者,随机分配至7天或14天抗生素治疗。
  • 共同主要可行性结局为招募率和治疗方案依从性。

主要发现

  • 共招募134例患者,历时47个中心-月,平均2.9例/中心-月(中位数1.0,范围0.1-4.4)。
  • 总体招募率超过BALANCE-ICU初步试验(平均1.10例/中心-月,p < 0.0001)。
  • 方案依从性为125/134(93%),高于BALANCE-ICU初步试验的89/115(77%)(p = 0.0003)。
  • 非ICU患者90天死亡率为17/133(12.8%),与ICU试验的17/115(14.8%)相当(p = 0.65)。
  • 模拟模型提示将入组扩展至非ICU患者对样本量和非劣效性界值的影响极小。

临床怎么用

  • 支持将BALANCE主试验扩展至非ICU病房,以增强结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal treatment duration for patients with bloodstream infection is understudied. The Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) pilot randomized clinical trial (RCT) determined that it was feasible to enroll and randomize intensive care unit (ICU) patients with bloodstream infection to 7 versus 14 days of treatment, and served as the vanguard for the ongoing BALANCE main RCT. We performed this BALANCE-Ward pilot RCT to examine the feasibility and impact of potentially extending the BALANCE main RCT to include patients hospitalized on non-ICU wards. METHODS: We conducted an open pilot RCT among a subset of six sites participating in the ongoing BALANCE RCT, randomizing patients with positive non-Staphylococcus aureus blood cultures on non-ICU wards to 7 versus 14 days of antibiotic treatment. The co-primary feasibility outcomes were recruitment rate and adherence to treatment duration protocol. We compared feasibility outcomes, patient/pathogen characteristics, and overall outcomes among those enrolled in this BALANCE-Ward and prior BALANCE-ICU pilot RCTs. We estimated the sample size and non-inferiority margin impacts of expanding the BALANCE main RCT to include non-ICU patients. RESULTS: A total of 134 patients were recruited over 47 site-months (mean 2.9 patients/site-month, median 1.0, range 0.1-4.4 patients/site-month). The overall recruitment rate exceeded the BALANCE-ICU pilot RCT (mean 1.10 patients/site-month, p < 0.0001). Overall protocol adherence also exceeded the adherence in the BALANCE-ICU pilot RCT (125/134, 93% vs 89/115, 77%, p = 0.0003). BALANCE-Ward patients were older, with lower Sequential Organ Failure Assessment scores, and higher proportions of infections caused by Escherichia coli and genito-urinary sources of bloodstream infection. The BALANCE-Ward pilot RCT patients had an overall 90-day mortality rate of 17/133 (12.8%), which was comparable to the 90-day mortality rate in the ICU pilot RCT (17/115, 14.8%) (p = 0.65). Simulation models indicated there would be minimal sample size and non-inferiority margin implications of expanding enrolment to increasing proportions of non-ICU versus ICU patients. CONCLUSION: It is feasible to enroll non-ICU patients in a trial of 7 versus 14 days of antibiotics for bloodstream infection, and expanding the BALANCE RCT hospital-wide has the potential to improve the timeliness and generalizability of trial results. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02917551. Registered on September 28, 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Daneman N, Rishu AH, Pinto R, et al. A pilot randomized controlled trial of 7 versus 14 days of antibiotic treatment for bloodstream infection on non-intensive care versus intensive care wards. Trials. 2020. PMID: 31941546. doi:10.1186/s13063-019-4033-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。